{"id":"chemotherapy-gemcitabine-based-regimen","safety":{"commonSideEffects":[{"rate":"40-70","effect":"Myelosuppression (neutropenia, thrombocytopenia, anemia)"},{"rate":"30-50","effect":"Nausea and vomiting"},{"rate":"30-40","effect":"Fatigue"},{"rate":"20-30","effect":"Elevated liver enzymes"},{"rate":"10-20","effect":"Rash"},{"rate":"<1","effect":"Hemolytic uremic syndrome (rare)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Gemcitabine is a deoxycytidine analog that interferes with DNA synthesis by inhibiting ribonucleotide reductase, an enzyme essential for deoxyribonucleotide production. Once incorporated into DNA during replication, it causes chain termination and triggers apoptosis. It is particularly effective against cells with high proliferation rates, making it useful in various solid tumors.","oneSentence":"Gemcitabine is a nucleoside analog that inhibits ribonucleotide reductase and gets incorporated into DNA, causing chain termination and apoptosis in rapidly dividing cancer cells.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:05:34.069Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Gemcitabine-based regimen for solid tumors (specific indication under investigation in phase 3 trial at Eye & ENT Hospital of Fudan University, likely head and neck or related malignancies)"}]},"trialDetails":[{"nctId":"NCT04267848","phase":"PHASE3","title":"Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2020-06-16","conditions":"Lung Non-Small Cell Carcinoma, Lung Non-Small Cell Squamous Carcinoma, Lung Non-Squamous Non-Small Cell Carcinoma","enrollment":1210},{"nctId":"NCT06694454","phase":"PHASE1, PHASE2","title":"Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC)","status":"NOT_YET_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-04-01","conditions":"Non-small Cell Lung Cancer (NSCLC), Carcinoma, Non-Small Cell Lung, Non-Small Cell Lung Carcinoma","enrollment":60},{"nctId":"NCT05771480","phase":"PHASE3","title":"Durvalumab With Chemotherapy as First Line Treatment in Patients With Advanced Biliary Tract Cancers (aBTCs)","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2023-08-16","conditions":"Biliary Tract Cancer","enrollment":142},{"nctId":"NCT07173751","phase":"PHASE3","title":"ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer","status":"RECRUITING","sponsor":"BioNTech SE","startDate":"2025-10-30","conditions":"Breast Neoplasms","enrollment":558},{"nctId":"NCT07362979","phase":"PHASE2","title":"Toripalimab Combined With Different Platinum-Based Induction Chemotherapy Regimens for Locally Advanced Nasopharyngeal Carcinoma","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2026-03-12","conditions":"Nasopharyngeal Cancinoma (NPC)","enrollment":243},{"nctId":"NCT06704724","phase":"PHASE1","title":"A Study to Learn About the Study Medicine PF-07985045 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Change in a Gene.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pfizer","startDate":"2024-12-10","conditions":"Carcinoma, Pancreatic Ductal, Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung","enrollment":30},{"nctId":"NCT07191418","phase":"NA","title":"Study-group on Palliative ERCP And RFA-ablation in Metastatic and Inoperable Pancreatic Tumors","status":"NOT_YET_RECRUITING","sponsor":"Roberto Valente","startDate":"2026-03","conditions":"Pancreatic Cancer Metastatic to Liver","enrollment":178},{"nctId":"NCT04222972","phase":"PHASE3","title":"A Study of Pralsetinib Versus Standard of Care for First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC)","status":"TERMINATED","sponsor":"Hoffmann-La Roche","startDate":"2020-07-24","conditions":"RET-fusion Non Small Cell Lung Cancer, Lung Neoplasm, Carcinoma, Non-Small-Cell Lung","enrollment":223},{"nctId":"NCT06447662","phase":"PHASE1","title":"A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation.","status":"RECRUITING","sponsor":"Pfizer","startDate":"2024-06-27","conditions":"Carcinoma, Pancreatic Ductal, Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung","enrollment":330},{"nctId":"NCT07432022","phase":"PHASE1, PHASE2","title":"A Phase I/II Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of the EMB-07 Combination Therapy in Patients With Aggressive B-Cell Non-Hodgkin Lymphoma","status":"NOT_YET_RECRUITING","sponsor":"Shanghai EpimAb Biotherapeutics Co., Ltd.","startDate":"2026-03-01","conditions":"Combination Therapy, Aggressive B-Cell Non-Hodgkin Lymphoma, EMB07","enrollment":115},{"nctId":"NCT03088540","phase":"PHASE3","title":"Study of REGN 2810 Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC)","status":"COMPLETED","sponsor":"Regeneron Pharmaceuticals","startDate":"2017-05-29","conditions":"Carcinoma，Non-Small-Cell Lung, Lung Carcinomas, Non-Small-Cell, Non-small-cell Lung Carcinoma","enrollment":712},{"nctId":"NCT07184047","phase":"","title":"Frailty Scales for Predicting Chemotherapy Toxicity in Older Adults With Gastrointestinal Cancers","status":"COMPLETED","sponsor":"Ankara Etlik City Hospital","startDate":"2024-01-15","conditions":"Gastrointestinal Cancers, Frailty, Sarcopenia in Elderly","enrollment":72},{"nctId":"NCT05475366","phase":"NA","title":"Personalized First-line Chemotherapy Choice in Advanced Pancreatic Adenocarcinoma Using Transcriptomic Signatures","status":"RECRUITING","sponsor":"Institut Curie","startDate":"2022-12-12","conditions":"Carcinoma, Pancreatic Ductal, Prognosis","enrollment":85},{"nctId":"NCT06290687","phase":"PHASE2","title":"Partial Cystectomy & Extended Pelvic Lymph Node Dissection With SOC Perioperative Systemic Therapy","status":"RECRUITING","sponsor":"Case Comprehensive Cancer Center","startDate":"2025-02-18","conditions":"Malignant Neoplasm of Bladder, Muscle Invasive Bladder Carcinoma","enrollment":40},{"nctId":"NCT07044453","phase":"PHASE2, PHASE3","title":"Risk-adapted Adjuvant Chemotherapy Guided by the Tumour Stage for Operated Pancreatic Adenocarcinoma Following Neoadjuvant Chemotherapy With mFOLFIRINOX","status":"RECRUITING","sponsor":"University Hospital, Rouen","startDate":"2025-12-08","conditions":"Resected Pancreatic Adenocarcinoma","enrollment":390},{"nctId":"NCT07415525","phase":"PHASE2","title":"IBI343 Combined With Chemotherapy as Neoadjuvant Therapy in Borderline Resectable Pancreatic Cancer","status":"NOT_YET_RECRUITING","sponsor":"Zhejiang University","startDate":"2026-02-01","conditions":"Pancreatic Cancer, Borderline Resectable Pancreatic Adenocarcinoma","enrollment":40},{"nctId":"NCT06829771","phase":"PHASE1, PHASE2","title":"Clinical Trial of TQB2825 Injection Combined Immunochemotherapy in Subjects With Diffuse Large B Cell Lymphoma","status":"RECRUITING","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2025-04-23","conditions":"Diffuse Large B Cell Lymphoma","enrollment":90},{"nctId":"NCT07312422","phase":"PHASE1, PHASE2","title":"LDRT Combined With Pucotenlimab and Standard Therapy for Advanced Pancreatic Cancer: A Single-Arm Study","status":"RECRUITING","sponsor":"Zhejiang Provincial People's Hospital","startDate":"2025-09-30","conditions":"Pancreatic Cancer, PD-L1, PD-1 Inhibitor","enrollment":10},{"nctId":"NCT07353294","phase":"PHASE1","title":"Propranolol With Tislelizumab Plus GC in Neoadjuvant Bladder UC","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2026-01-01","conditions":"Bladder Urothelial Carcinoma, Lymph Node Metastasis","enrollment":12},{"nctId":"NCT06574620","phase":"NA","title":"Using Tumour DNA and Proteins to Better Understand How Pancreatic Cancer Responds to Treatment","status":"RECRUITING","sponsor":"British Columbia Cancer Agency","startDate":"2025-11-28","conditions":"Pancreatic Ductal Adenocarcinoma, Resectable Pancreatic Ductal Adenocarcinoma, Borderline Resectable Pancreatic Ductal Adenocarcinoma","enrollment":200},{"nctId":"NCT07340164","phase":"PHASE2","title":"Trastzumab Deruxtecan Versus SOC in Recurrent Ovarian That Progressed on Prior PARP Inhibitor Therapy","status":"NOT_YET_RECRUITING","sponsor":"Yonsei University","startDate":"2025-12-30","conditions":"Ovarian Cancer, Ovarian Carcinoma, Recurrent, Ovarian Cancer Metastatic Recurrent","enrollment":116},{"nctId":"NCT06908304","phase":"PHASE3","title":"A Phase III Study With THIO + Cemiplimab vs Chemotherapy as 3rd Line Treatment in Advanced/Metastatic NSCLC","status":"RECRUITING","sponsor":"Maia Biotechnology","startDate":"2025-12-08","conditions":"Carcinoma, Non-Small -Cell Lung","enrollment":300},{"nctId":"NCT07235202","phase":"PHASE1, PHASE2","title":"A Study of MR001 Combined With Chemotherapy in Patients With Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) After First-line Therapy","status":"RECRUITING","sponsor":"Shenzhen Majory Biotechnology Co., Ltd.","startDate":"2025-12-24","conditions":"Pancreatic Ductal Adenocarcinoma (PDAC)","enrollment":45},{"nctId":"NCT06120374","phase":"","title":"Adjuvant Radioimmunotherapy Compared With Adjuvant Chemotherapy for UTUC","status":"RECRUITING","sponsor":"Peking University First Hospital","startDate":"2022-01-01","conditions":"Urothelial Carcinoma","enrollment":178},{"nctId":"NCT07296705","phase":"PHASE2","title":"Neoadjuvant Zanidatamab + Tislelizumab + Chemotherapy for Selective Bladder Preservation in HER2-Positive MIBC","status":"RECRUITING","sponsor":"Fujian Medical University Union Hospital","startDate":"2025-10-25","conditions":"Muscle Invasive Bladder Cancer (MIBC)","enrollment":25},{"nctId":"NCT07267078","phase":"PHASE2","title":"Tuvonralimab and Iparomlimab Based Regimens for the Neoadjuvant Treatment of Biliary Tract Cancer","status":"RECRUITING","sponsor":"Peking Union Medical College Hospital","startDate":"2025-05-25","conditions":"Biliary Tract Cancer","enrollment":45},{"nctId":"NCT07248696","phase":"NA","title":"Tislelizumab Plus Chemotherapy With Response-Adapted Radiotherapy for de Novo Metastatic Nasopharyngeal Carcinoma: A Prospective, Phase II Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"Chongqing University Cancer Hospital","startDate":"2025-10-04","conditions":"Nasopharyngeal Cancinoma (NPC)","enrollment":32},{"nctId":"NCT06889610","phase":"PHASE2","title":"A Phase II Clinical Study of Multimodal Ablation Combined With Systemic Drug Therapy for Advanced Solid Tumors.","status":"RECRUITING","sponsor":"Fudan University","startDate":"2025-11-04","conditions":"Triple Negative Breast Cancer Metastatic, Melanoma Metastatic, Colorectal Cancer Metastatic","enrollment":95},{"nctId":"NCT03193190","phase":"PHASE1, PHASE2","title":"A Study of Multiple Immunotherapy-Based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2017-07-05","conditions":"Pancreatic Adenocarcinoma","enrollment":341},{"nctId":"NCT03217097","phase":"NA","title":"MGMT-NET: O6-methylguanine-DNA Methyltransferase (MGMT) Status in Neuroendocrine Tumors: Predictive Factor of Response to Alkylating Agents","status":"COMPLETED","sponsor":"Hospices Civils de Lyon","startDate":"2018-10-16","conditions":"Neuroendocrine Tumors","enrollment":116},{"nctId":"NCT03484299","phase":"PHASE1","title":"Chemotherapy and Irreversible Electroporation in the Treatment of Advanced Pancreatic Adenocarcinoma","status":"RECRUITING","sponsor":"University of Louisville","startDate":"2018-05-30","conditions":"Pancreas Cancer","enrollment":20},{"nctId":"NCT07202819","phase":"NA","title":"Effect of Neoadjuvant Chemotherapy on MRI Accuracy Before Cystectomy","status":"RECRUITING","sponsor":"Assiut University","startDate":"2025-09-01","conditions":"Muscle Invasive Bladder Cancer","enrollment":76},{"nctId":"NCT05870748","phase":"PHASE2, PHASE3","title":"REFRaME-O1: A Study to Investigate the Efficacy and Safety of Luveltamab Tazevibulin Versus Investigator's Choice (IC) Chemotherapy in Women With Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing FOLR1","status":"TERMINATED","sponsor":"Sutro Biopharma, Inc.","startDate":"2023-07-12","conditions":"Ovarian Cancer, Epithelial Ovarian Cancer, Fallopian Tube Cancer","enrollment":600},{"nctId":"NCT07171528","phase":"PHASE2","title":"Secondary Cytoreductive Surgery After Chemotherapy for Recurrent Epithelial Ovarian Cancer","status":"RECRUITING","sponsor":"National Cancer Center, Korea","startDate":"2025-09-10","conditions":"Ovarian Cancer","enrollment":80},{"nctId":"NCT07160283","phase":"PHASE2","title":"The Efficacy and Safety of Trilaciclib in Bone Marrow Protection Before Chemotherapy for Advanced Bile Duct Cancer and Pancreatic Cancer","status":"NOT_YET_RECRUITING","sponsor":"The Second Affiliated Hospital of Shandong First Medical University","startDate":"2025-09-01","conditions":"Biliary Tract Neoplasms, Pancreatic Neoplasms","enrollment":96},{"nctId":"NCT07155044","phase":"","title":"A Comparative Study of Neoadjuvant Chemotherapy Versus Upfront Radical Surgery for Upper Tract Urothelial Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Changhai Hospital","startDate":"2024-05-15","conditions":"UTUC, UC (Urothelial Cancer)","enrollment":120},{"nctId":"NCT07156058","phase":"NA","title":"MiniPDX-based Postoperative Adjuvant Therapy for Biliary Tract Cancer","status":"RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2023-01-01","conditions":"Biliary Tract Cancer","enrollment":204},{"nctId":"NCT05821556","phase":"PHASE2","title":"Valproic Acid/Simvastatin Plus Gemcitabine/Nab-paclitaxel Based Regimens in Untreated Metastatic Pancreatic Adenocarcinoma Patients","status":"RECRUITING","sponsor":"National Cancer Institute, Naples","startDate":"2023-06-12","conditions":"Adenocarcinoma of the Pancreas","enrollment":240},{"nctId":"NCT07053150","phase":"PHASE2","title":"A Prospective, Open-label, Exploratory Basket Trial to Evaluate the Efficacy and Safety of Sintilimab Combined With Pyrotinib ± Chemotherapy in Patients With Advanced Digestive System Tumors","status":"NOT_YET_RECRUITING","sponsor":"Tongji Hospital","startDate":"2025-08-15","conditions":"Advanced Digestive System Tumor","enrollment":80},{"nctId":"NCT06228079","phase":"PHASE3","title":"Adjuvant vs Surgery Only in Early-stage Recurrent NPC","status":"RECRUITING","sponsor":"Eye & ENT Hospital of Fudan University","startDate":"2024-06-25","conditions":"Recurrent Nasopharyngeal Carcinoma","enrollment":176},{"nctId":"NCT04594772","phase":"PHASE2","title":"Adaptive Approach to Neoadjuvant Therapy to Maximize Resection Rates for Pancreatic Adenocarcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Cincinnati","startDate":"2021-03-17","conditions":"Pancreas Cancer","enrollment":32},{"nctId":"NCT06311981","phase":"PHASE2","title":"Carbon Ion Radiotherapy for Locally Advanced Lung Cancer in Elderly Patients","status":"RECRUITING","sponsor":"Jian Chen","startDate":"2024-08-08","conditions":"Non-small Cell Lung Cancer, Older People, Carbon Ion Radiotherapy","enrollment":29},{"nctId":"NCT06438822","phase":"PHASE2","title":"Cadonilimab Combined With Liposomal Irinotecan Plus Leucovorin and Fluorouracil for Advanced Cholangiocarcinoma","status":"RECRUITING","sponsor":"West China Hospital","startDate":"2024-08-30","conditions":"Cholangiocarcinoma","enrollment":51},{"nctId":"NCT04229004","phase":"PHASE3","title":"A Multi-center Trial to Evaluate Multiple Regimens in Metastatic Pancreatic Cancer","status":"COMPLETED","sponsor":"Pancreatic Cancer Action Network","startDate":"2020-01-31","conditions":"Metastatic Pancreatic Cancer, Metastatic Pancreatic Adenocarcinoma","enrollment":502},{"nctId":"NCT06493552","phase":"PHASE2, PHASE3","title":"Modular Trial of sEphB4-HSA in EphrinB2-High Solid Tumors","status":"RECRUITING","sponsor":"Vasgene Therapeutics, Inc","startDate":"2025-03-15","conditions":"Muscle-Invasive Bladder Carcinoma, Metastatic Urothelial Carcinoma","enrollment":700},{"nctId":"NCT06904573","phase":"PHASE2","title":"Probiotics in Advanced Urothelial Carcinoma","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2025-01-01","conditions":"Advanced Urothelial Carcinoma, Probiotics, Immunotherapy","enrollment":222},{"nctId":"NCT06888674","phase":"PHASE1, PHASE2","title":"Personalized Tumor Neoantigen MRNA Therapy Adjuvant Treatment for Postoperative Pancreatic Cancer.","status":"NOT_YET_RECRUITING","sponsor":"Zhejiang University","startDate":"2025-04-01","conditions":"Pancreatic Cancer Resectable","enrollment":60},{"nctId":"NCT02489903","phase":"PHASE2","title":"RRx-001 in Lung Cancer, Ovarian Cancer and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT)","status":"COMPLETED","sponsor":"EpicentRx, Inc.","startDate":"2015-06","conditions":"Small Cell Carcinoma, Carcinoma, Non-Small-Cell Lung, Neuroendocrine Tumors","enrollment":139},{"nctId":"NCT06867146","phase":"NA","title":"MRD in PAAD Adjuvant Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Peking Union Medical College Hospital","startDate":"2024-10-15","conditions":"The Role of Molecular Residual Disease in the Treatment Strategy and Prognosis Prediction of Pancreatic Cancer Patients Undergoing Adjuvant Therapy, Molecular Residual Disease, Pancreatic Cancer","enrollment":60},{"nctId":"NCT04544969","phase":"","title":"Detecting Chemosensitivity and Predicting Treatmemt Efficacy With CTCs in mNPC","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2020-04-01","conditions":"Circulating Tumor Cell, Nasopharyngeal Carcinoma, Distant Metastases.Clinical","enrollment":50},{"nctId":"NCT04423731","phase":"","title":"Neoadjuvant Chemotherapy in Borderline Resectable and Locally Advanced Pancreatic Cancer (NORPACT-2)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Oslo University Hospital","startDate":"2018-01-01","conditions":"Locally Advanced Pancreatic Adenocarcinoma, Chemotherapy Effect, Borderline Resectable Pancreatic Adenocarcinoma","enrollment":251},{"nctId":"NCT04989218","phase":"PHASE1, PHASE2","title":"Durvalumab and Tremelimumab With Platinum-based Chemotherapy in Intrahepatic Cholangiocarcinoma (ICC)","status":"TERMINATED","sponsor":"University of Alabama at Birmingham","startDate":"2023-01-30","conditions":"Cholangiocarcinoma","enrollment":1},{"nctId":"NCT06652022","phase":"NA","title":"Radiotherapy Combined with Systemic Therapy Versus Systemic Therapy for Oligometastatic UTUCs","status":"RECRUITING","sponsor":"Peking University First Hospital","startDate":"2022-01-01","conditions":"Oligometastatic Disease, Ureter Cancer, Renal Pelvic Carcinoma","enrollment":102},{"nctId":"NCT06649448","phase":"NA","title":"A Multi-cohort Study of Efbemalenograstim Alfa Injection for Preventing ANC Reduction in Solid Tumor Patients Post Immune-chemotherapy.","status":"NOT_YET_RECRUITING","sponsor":"Shandong Cancer Hospital and Institute","startDate":"2024-10-10","conditions":"Solid Tumor Cancer, Chemotherapy Induced Neutropenia, G-CSF","enrollment":200},{"nctId":"NCT04999761","phase":"PHASE1","title":"AB122 Platform Study","status":"RECRUITING","sponsor":"Taiho Pharmaceutical Co., Ltd.","startDate":"2021-06-01","conditions":"Advanced or Metastatic Solid Tumor, Pancreatic Ductal Adenocarcinoma, Colorectal Cancer","enrollment":917},{"nctId":"NCT03598270","phase":"PHASE3","title":"Platinum-based Chemotherapy With Atezolizumab and Niraparib in Patients With Recurrent Ovarian Cancer","status":"COMPLETED","sponsor":"Grupo Español de Investigación en Cáncer de Ovario","startDate":"2018-11-21","conditions":"Recurrent Ovarian Carcinoma","enrollment":417},{"nctId":"NCT04498767","phase":"NA","title":"Stereotactic Body Radiotherapy in Patients With Rare Oligometastatic Cancers (OligoRARE)","status":"RECRUITING","sponsor":"European Organisation for Research and Treatment of Cancer - EORTC","startDate":"2021-06-10","conditions":"Gynecologic Cancer, Skin Cancer, Head and Neck Cancer","enrollment":200},{"nctId":"NCT04931420","phase":"PHASE2","title":"Study Comparing Standard of Care Chemotherapy With/ Without Sequential Cytoreductive Surgery for Patients With Metastatic Foregut Cancer and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid Levels","status":"WITHDRAWN","sponsor":"University of Chicago","startDate":"2022-05-19","conditions":"Metastatic Cancer, Foregut Carcinoid Tumor, Gastric Adenocarcinoma","enrollment":""},{"nctId":"NCT02352948","phase":"PHASE3","title":"A Global Study to Assess the Effects of MEDI4736 (Durvalumab), Given as Monotherapy or in Combination With Tremelimumab Determined by PD-L1 Expression Versus Standard of Care in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2015-01-13","conditions":"Non - Small Cell Lung Cancer NSCLC","enrollment":597},{"nctId":"NCT06467500","phase":"PHASE2","title":"A Prospective, Open-label, Single-center, Single-arm Phase II Clinical Study of Cadonilimab (AK104) Combined With Monotherapy Chemotherapy in Patients With Advanced Non-small Cell Lung Cancer With Negative Driver Genes and Failed Immunotherapy","status":"RECRUITING","sponsor":"Xin-Hua Xu","startDate":"2024-03-01","conditions":"Non-small Cell Lung Cancer","enrollment":48},{"nctId":"NCT06427057","phase":"PHASE2","title":"A Study of Cadonilimab（AK104）Combined With Standard Treatment for Function Preservation in Urinary System Tumors","status":"NOT_YET_RECRUITING","sponsor":"Tongji Hospital","startDate":"2024-07-01","conditions":"Urinary System Tumor","enrollment":40},{"nctId":"NCT06424899","phase":"PHASE2","title":"A Study Comparing Neoadjuvant Chemoimmunotherapy and Immuno-consolidationafter Compared With Immunoconsolidation After Radical Chemoradiotherapy for Stage III Potentially Resectable NSCLC","status":"RECRUITING","sponsor":"Zeng Jian","startDate":"2024-05-19","conditions":"Non Small Cell Lung Cancer","enrollment":92},{"nctId":"NCT06345599","phase":"PHASE1, PHASE2","title":"PRaG Therapy in Combination With Locally Advanced Pancreatic Ductal Adenocarcinoma (PDAC) (NeoPRAG Study)","status":"NOT_YET_RECRUITING","sponsor":"Second Affiliated Hospital of Soochow University","startDate":"2024-05-01","conditions":"Pancreatic Ductal Adenocarcinoma","enrollment":66},{"nctId":"NCT05711628","phase":"PHASE3","title":"A Trial Comparing Chemotherapy Versus Novel Immune Checkpoint Inhibitor (Pembrolizumab) Plus Chemotherapy in Treating Relapsed/Refractory Classical Hodgkin Lymphoma","status":"WITHDRAWN","sponsor":"National Cancer Institute (NCI)","startDate":"2023-08-10","conditions":"Recurrent Classic Hodgkin Lymphoma, Refractory Classic Hodgkin Lymphoma","enrollment":""},{"nctId":"NCT05861830","phase":"PHASE3","title":"Dalpiciclib With Endocrine Therapy for Advanced Breast Cancer After CDK4/6 Inhibitor Failure (DAWNA-FES)","status":"RECRUITING","sponsor":"Peking Union Medical College Hospital","startDate":"2023-05-15","conditions":"Advanced Breast Cancer","enrollment":80},{"nctId":"NCT06255210","phase":"PHASE2","title":"Efficacy and Safety of Induction Chemotherapy for Olfactory Neuroblastoma (ESICON)","status":"RECRUITING","sponsor":"Hongmeng Yu","startDate":"2024-03-01","conditions":"Olfactory Neuroblastoma","enrollment":25},{"nctId":"NCT06208436","phase":"","title":"The Survival Outcome of Adjuvant Chemotherapy for Stage I Pancreatic Cancer","status":"UNKNOWN","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2023-10-07","conditions":"Pancreas Cancer, Chemotherapy","enrollment":250},{"nctId":"NCT01897454","phase":"PHASE2","title":"Gemcitabine Hydrochloride, and Radiation Therapy in Patients With Borderline Resectable Pancreatic Cancer","status":"TERMINATED","sponsor":"Albert Einstein College of Medicine","startDate":"2012-01-27","conditions":"Pancreatic Adenocarcinoma, Stage IIA Pancreatic Cancer, Stage IIB Pancreatic Cancer","enrollment":23},{"nctId":"NCT03737123","phase":"PHASE2","title":"Trial of Atezolizumab Plus Chemotherapy After Progression on PD-1 or PD-L1 in Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma","status":"TERMINATED","sponsor":"Nabil Adra","startDate":"2018-12-19","conditions":"Urothelial Carcinoma","enrollment":6},{"nctId":"NCT05959395","phase":"NA","title":"Hyperthermia Treatment Added to Chemotherapy Standard of Care for Pancreatic Tumors","status":"UNKNOWN","sponsor":"NeoTherma Oncology","startDate":"2023-08-15","conditions":"Pancreatic Cancer","enrollment":5},{"nctId":"NCT02805530","phase":"NA","title":"Radical Treatment of Synchronous Oligometastatic Non-Small Cell Lung Carcinoma","status":"COMPLETED","sponsor":"Instituto Nacional de Cancerologia de Mexico","startDate":"2015-06","conditions":"Carcinoma, Non-Small-Cell Lung, Synchronous Neoplasms","enrollment":36},{"nctId":"NCT03472274","phase":"PHASE2","title":"Durvalumab (MEDI4736) and TREmelimumab in NEOadjuvant Bladder Cancer Patients (DUTRENEO)","status":"COMPLETED","sponsor":"Fundacion CRIS de Investigación para Vencer el Cáncer","startDate":"2018-10-25","conditions":"Bladder Cancer","enrollment":101},{"nctId":"NCT05255471","phase":"PHASE3","title":"MITO 35B: Olaparib Beyond Progression Compared to Platinum Chemotherapy After Secondary Cytoreductive Surgery in Recurrent Ovarian Cancer Patients.","status":"RECRUITING","sponsor":"National Cancer Institute, Naples","startDate":"2022-01-21","conditions":"Ovarian Cancer","enrollment":200},{"nctId":"NCT05628922","phase":"PHASE2","title":"Modulation Therapy for Locally Advanced NPC Based on Plasma EBV DNA Level Post-ICT","status":"RECRUITING","sponsor":"Fudan University","startDate":"2022-07-02","conditions":"Nasopharyngeal Cancer","enrollment":198},{"nctId":"NCT05383001","phase":"PHASE2","title":"Randomized Phase II, Open-label Efficacy and Safety Study of Second-line Durvalumab Plus Tremelimumab Versus Platinum-based Chemotherapy Alone in Patients With NSCLC and First-line Checkpoint-inhibitor Therapy (Re-Check)","status":"WITHDRAWN","sponsor":"AIO-Studien-gGmbH","startDate":"2022-05-20","conditions":"NSCLC Stage IV","enrollment":""},{"nctId":"NCT04769414","phase":"PHASE2","title":"Flouro-Gem in Adenocarcinoma of the Pancreas (GEFLUPAN)","status":"COMPLETED","sponsor":"Menoufia University","startDate":"2021-02-20","conditions":"Cancer of Pancreas, Chemotherapy Effect, Metastatic Pancreatic Cancer","enrollment":48},{"nctId":"NCT05487443","phase":"PHASE2, PHASE3","title":"The Efficacy of Chemotherapy Combined With Immunocheckpoint Inhibitors in Advanced Biliary Malignancies","status":"UNKNOWN","sponsor":"First People's Hospital of Hangzhou","startDate":"2022-08-01","conditions":"Gemcitabine, Biliary Tract Cancer, Immune Checkpoint Inhibitors","enrollment":50},{"nctId":"NCT04931394","phase":"PHASE3","title":"Organoid-Guided Adjuvant Chemotherapy for Pancreatic Cancer","status":"UNKNOWN","sponsor":"Changhai Hospital","startDate":"2021-06-01","conditions":"Pancreatic Cancer","enrollment":200},{"nctId":"NCT04931381","phase":"PHASE3","title":"Organoid-Guided Chemotherapy for Advanced Pancreatic Cancer","status":"UNKNOWN","sponsor":"Changhai Hospital","startDate":"2021-06-01","conditions":"Advanced Pancreatic Cancer","enrollment":100},{"nctId":"NCT05247996","phase":"NA","title":"TACE Combined With \"Target Immune\" Therapy for First-line Treatment in the Treatment of Intrahepatic Cholangiocarcinoma","status":"UNKNOWN","sponsor":"The Central Hospital of Lishui City","startDate":"2022-03-01","conditions":"Intrahepatic Cholangiocarcinoma","enrollment":98},{"nctId":"NCT05233358","phase":"NA","title":"HAIC Combined With Second-line \"Target Immunity\" for HCC With TACE Standard Treatment Low Response or Failure","status":"UNKNOWN","sponsor":"The Central Hospital of Lishui City","startDate":"2022-02-01","conditions":"Hepatocellular Carcinoma","enrollment":176},{"nctId":"NCT01303172","phase":"PHASE2","title":"A Trial Comparing Gemcitabine With and Without IMM-101 in Advanced Pancreatic Cancer","status":"COMPLETED","sponsor":"Immodulon Therapeutics Ltd","startDate":"2011-06","conditions":"Advanced Pancreatic Cancer","enrollment":110},{"nctId":"NCT04586465","phase":"PHASE2","title":"Dynamic PET/CT Evaluated the Response of Neoadjuvant Anti-PD1 Combination With Chemotherapy for Ⅱa-Ⅲb NSCLC","status":"UNKNOWN","sponsor":"Fifth Affiliated Hospital, Sun Yat-Sen University","startDate":"2020-10-10","conditions":"Non-small Cell Lung Cancer Stage II, Non-small Cell Lung Cancer Stage III, PET/CT","enrollment":23},{"nctId":"NCT04897854","phase":"PHASE3","title":"Timing of Start of systemIc Treatment for Asymptomatic Metastasized Pancreatic Cancer","status":"UNKNOWN","sponsor":"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","startDate":"2021-04-22","conditions":"Metastatic Pancreas Cancer","enrollment":184},{"nctId":"NCT03986528","phase":"PHASE4","title":"Clinical Trial of Kanglaite Injection (KLTi) in Advanced Non-Small Cell Lung Cancer (NSCLC)","status":"UNKNOWN","sponsor":"Jie Li","startDate":"2019-08-28","conditions":"NSCLC","enrollment":334},{"nctId":"NCT04764149","phase":"","title":"Platinum Plus Low-dose Long-term Continuous Intravenous Infused 5-Fluorouracil in Recurrent Nasopharyngeal Carcinoma","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2019-11-01","conditions":"Nasopharyngeal Carcinoma","enrollment":801},{"nctId":"NCT02579616","phase":"PHASE2","title":"Study of Lenvatinib (E7080) in Unresectable Biliary Tract Cancer (BTC) Who Failed Gemcitabine-based Combination Chemotherapy","status":"COMPLETED","sponsor":"Eisai Co., Ltd.","startDate":"2015-10-23","conditions":"Biliary Tract Cancer","enrollment":29},{"nctId":"NCT04677192","phase":"PHASE2","title":"Microwave Ablation Combined With Chemotherapy in the Treatment of Pancreatic Cancer Oligohepatic Metastasis","status":"UNKNOWN","sponsor":"Fudan University","startDate":"2021-01","conditions":"Pancreatic Cancer Metastatic to Liver, Oligometastasis","enrollment":50},{"nctId":"NCT02951156","phase":"PHASE3","title":"Avelumab In Combination Regimens That Include An Immune Agonist, Epigenetic Modulator, CD20 Antagonist and/or Conventional Chemotherapy in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL)","status":"TERMINATED","sponsor":"Pfizer","startDate":"2016-12-16","conditions":"Diffuse Large B-Cell Lymphoma","enrollment":29},{"nctId":"NCT02788201","phase":"PHASE2","title":"Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2017-03-27","conditions":"Urothelial Carcinoma, Bladder Cancer, Urinary Bladder Neoplasms","enrollment":8},{"nctId":"NCT03402048","phase":"PHASE3","title":"The EPIC Trial The Elderly Patient Individualized Chemotherapy Trial","status":"UNKNOWN","sponsor":"University of Turin, Italy","startDate":"2012-07","conditions":"Stage IV, NSCLC, Lung Neoplasms, Bronchial Neoplasms","enrollment":567},{"nctId":"NCT02658214","phase":"PHASE1","title":"Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid Tumors","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2016-04-28","conditions":"Small Cell Lung Carcinoma, Carcinoma, Squamous Cell of Head and Neck, Stomach Neoplasms","enrollment":32},{"nctId":"NCT04472403","phase":"","title":"Platinum Plus Low-dose Long-term Continuous Intravenous Infused 5-Fluorouracil in Metastatic Nasopharyngeal Carcinoma","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2019-11-26","conditions":"Nasopharyngeal Carcinoma, Metastasis, Chemotherapy","enrollment":2000},{"nctId":"NCT03403049","phase":"PHASE1","title":"Carbon Ion Radiation Therapy for Locally Advanced Pancreatic Cancer","status":"COMPLETED","sponsor":"Albert Einstein College of Medicine","startDate":"2016-04-01","conditions":"Pancreatic Cancer, Cancer","enrollment":14},{"nctId":"NCT03823625","phase":"PHASE2","title":"An Open-label, Randomized, Parallel, Non Comparative, Phase II Trial of Nivolumab Plus Ipilimumab Versus Platinum-based Chemotherapy Plus Nivolumab in Chemonaive Metastatic or Recurrent Squamous-Cell Lung Cancer (SqLC)","status":"UNKNOWN","sponsor":"Fondazione Ricerca Traslazionale","startDate":"2017-09-13","conditions":"Squamous-Cell Lung Cancer","enrollment":112},{"nctId":"NCT02716896","phase":"NA","title":"Radical Cystectomy Compared With Chemoradiation for Muscle Invasive Bladder Cancer","status":"TERMINATED","sponsor":"The University of Texas Health Science Center at San Antonio","startDate":"2016-05","conditions":"Muscle Invasive Bladder Cancer","enrollment":2},{"nctId":"NCT04124731","phase":"PHASE2","title":"Combination Therapy of Sintilimab and Anlotinib as a First-line Treatment in Advanced NSCLC (SUNRISE)","status":"UNKNOWN","sponsor":"Shanghai Chest Hospital","startDate":"2019-10","conditions":"Carcinoma, Non-small Cell Lung Cancer","enrollment":98},{"nctId":"NCT01505530","phase":"PHASE2","title":"A Phase 2 Study of LY2495655 in Participants With Pancreatic Cancer","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2011-12","conditions":"Pancreatic Cancer","enrollment":125},{"nctId":"NCT03398291","phase":"PHASE3","title":"Simultaneous Resection of Pancreatic Cancer and Liver Oligometastasis After Induction Chemotherapy","status":"UNKNOWN","sponsor":"Fudan University","startDate":"2018-07-01","conditions":"Pancreatic Cancer, Liver Metastases, Surgery","enrollment":300},{"nctId":"NCT02620423","phase":"PHASE1","title":"Study of Pembrolizumab With REOLYSIN® and Chemotherapy in Patients With Advanced Pancreatic Adenocarcinoma","status":"COMPLETED","sponsor":"Oncolytics Biotech","startDate":"2015-12","conditions":"Pancreatic Adenocarcinoma","enrollment":11}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":71,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Chemotherapy,Gemcitabine based regimen","genericName":"Chemotherapy,Gemcitabine based regimen","companyName":"Eye & ENT Hospital of Fudan University","companyId":"eye-ent-hospital-of-fudan-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Gemcitabine is a small molecule used in chemotherapy regimens, particularly for treating non-small cell lung cancer (NSCLC) stages II and III, as well as other conditions such as oligometastatic disease and ureter cancer. It is often combined with other treatments, including pembrolizumab, pemetrexed, cisplatin, and carboplatin, as part of a systemic therapy regimen.","enrichmentLevel":3,"visitCount":2,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}